Literature DB >> 23955073

PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.

Linhua Jin1, Yoko Tabe1,2, Kensuke Kojima2, Masato Shikami3, Julina Benito2, Vivian Ruvolo2, Rui-Yu Wang2, Teresa McQueen2, Stefan O Ciurea4, Takashi Miida1, Michael Andreeff2,4, Marina Konopleva2,4.   

Abstract

UNLABELLED: Both phosphatidylinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin signaling and antiapoptotic Bcl-2 family members are critical for survival of acute myeloid leukemia (AML) cells. Here, we demonstrate the antileukemic effects of simultaneous inhibition of PI3K by the selective class I PI3K inhibitor GDC-0941 and of Bcl-2 family members by the BH3 mimetic ABT-737 in the context of the bone marrow microenvironment, where hypoxia and interactions with bone marrow stromal cells promote AML cell survival and chemoresistance. The combination of GDC-0941 and ABT-737 profoundly downregulated antiapoptotic Mcl-1 expression levels, activated BAX, and induced mitochondrial apoptosis in AML cells co-cultured with bone marrow stromal cells under hypoxic conditions. Hypoxia caused degradation of Mcl-1 and rendered Mcl-1-overexpressing OCI-AML3 cells sensitive to ABT-737. Our findings suggest that pharmacologic PI3K inhibition by GDC-0941 enhances ABT-737-induced leukemia cell death even under the protective conditions afforded by the bone marrow microenvironment. KEY MESSAGE: Combined blockade of PI3K and Bcl-2 pathways down-regulates anti-apoptotic Mcl-1 expression PI3K and Bcl-2 induced Mcl-1 down-regulation activates BAX PI3K and Bcl-2 blockage induces apoptosis in AML under hypoxic BM microenvironment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23955073      PMCID: PMC3834093          DOI: 10.1007/s00109-013-1076-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  39 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Authors:  M Konopleva; M Milella; P Ruvolo; J C Watts; M R Ricciardi; B Korchin; T McQueen; W Bornmann; T Tsao; P Bergamo; D H Mak; W Chen; J McCubrey; A Tafuri; M Andreeff
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

3.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

4.  DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses.

Authors:  Sophie Vasseur; Samia Afzal; Joël Tardivel-Lacombe; David S Park; Juan Lucio Iovanna; Tak Wah Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-14       Impact factor: 11.205

5.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.

Authors:  M Konopleva; S Konoplev; W Hu; A Y Zaritskey; B V Afanasiev; M Andreeff
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

6.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Authors:  Adrian J Folkes; Khatereh Ahmadi; Wendy K Alderton; Sonia Alix; Stewart J Baker; Gary Box; Irina S Chuckowree; Paul A Clarke; Paul Depledge; Suzanne A Eccles; Lori S Friedman; Angela Hayes; Timothy C Hancox; Arumugam Kugendradas; Letitia Lensun; Pauline Moore; Alan G Olivero; Jodie Pang; Sonal Patel; Giles H Pergl-Wilson; Florence I Raynaud; Anthony Robson; Nahid Saghir; Laurent Salphati; Sukhjit Sohal; Mark H Ultsch; Melanie Valenti; Heidi J A Wallweber; Nan Chi Wan; Christian Wiesmann; Paul Workman; Alexander Zhyvoloup; Marketa J Zvelebil; Stephen J Shuttleworth
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

Review 7.  Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.

Authors:  M Vogler; D Dinsdale; M J S Dyer; G M Cohen
Journal:  Cell Death Differ       Date:  2008-09-19       Impact factor: 15.828

8.  Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.

Authors:  Juliana Benito; Yuexi Shi; Barbara Szymanska; Hernan Carol; Ingrid Boehm; Hongbo Lu; Sergej Konoplev; Wendy Fang; Patrick A Zweidler-McKay; Dario Campana; Gautam Borthakur; Carlos Bueso-Ramos; Elizabeth Shpall; Deborah A Thomas; Craig T Jordan; Hagop Kantarjian; William R Wilson; Richard Lock; Michael Andreeff; Marina Konopleva
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

9.  Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.

Authors:  Kari Högstrand; Eduar Hejll; Birgitta Sander; Björn Rozell; Lars-Gunnar Larsson; Alf Grandien
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

10.  Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.

Authors:  Lindsay C Spender; Gareth J Inman
Journal:  Mol Cancer Res       Date:  2012-01-12       Impact factor: 5.852

View more
  4 in total

Review 1.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.

Authors:  Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai
Journal:  Cancer Discov       Date:  2017-11-16       Impact factor: 39.397

2.  Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.

Authors:  Mohamed Rahmani; Mandy Mayo Aust; Elisa Hawkins; Rebecca E Parker; Masey Ross; Maciej Kmieciak; Leonid Borisovich Reshko; Kathryn A Rizzo; Catherine I Dumur; Andrea Ferreira-Gonzalez; Steven Grant
Journal:  Haematologica       Date:  2015-10-09       Impact factor: 11.047

3.  Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.

Authors:  Stefano Iacovelli; Maria Rosaria Ricciardi; Matteo Allegretti; Simone Mirabilii; Roberto Licchetta; Paola Bergamo; Cinzia Rinaldo; Ann Zeuner; Robin Foà; Michele Milella; James A McCubrey; Alberto M Martelli; Agostino Tafuri
Journal:  Oncotarget       Date:  2015-10-13

Review 4.  Rational Combinations of Targeted Agents in AML.

Authors:  Prithviraj Bose; Steven Grant
Journal:  J Clin Med       Date:  2015-04-10       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.